These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Role of the immune response in BCG for bladder cancer. Ratliff TL Eur Urol; 1992; 21 Suppl 2():17-21. PubMed ID: 1396942 [TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma. Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Annoscia S; Lozzi C; Betta PG Eur Urol; 1992; 21(4):304-8. PubMed ID: 1459153 [TBL] [Abstract][Full Text] [Related]
4. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells. Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930 [TBL] [Abstract][Full Text] [Related]
5. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model. Yoshino T; Miyazaki J; Kojima T; Kandori S; Shiga M; Kawahara T; Kimura T; Naka T; Kiyohara H; Watanabe M; Yamasaki S; Akaza H; Yano I; Nishiyama H PLoS One; 2019; 14(1):e0209196. PubMed ID: 30608942 [TBL] [Abstract][Full Text] [Related]
6. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway. Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321 [TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer. Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038 [TBL] [Abstract][Full Text] [Related]
8. Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG: a model to study tuberculosis immunity. Ponticiello A; Perna F; Maione S; Stradolini M; Testa G; Terrazzano G; Ruggiero G; Malerba M; Sanduzzi A Respir Med; 2004 Jun; 98(6):509-14. PubMed ID: 15191035 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831 [TBL] [Abstract][Full Text] [Related]
11. Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. Chin JL; Kadhim SA; Batislam E; Karlik SJ; Garcia BM; Nickel JC; Morales A J Urol; 1996 Sep; 156(3):1189-93. PubMed ID: 8709344 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer. Gan YH; Mahendran R; James K; Lawrencia C; Esuvaranathan K Clin Immunol; 1999 Feb; 90(2):230-7. PubMed ID: 10080835 [TBL] [Abstract][Full Text] [Related]
13. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Thanhäuser A; Böhle A; Flad HD; Ernst M; Mattern T; Ulmer AJ Cancer Immunol Immunother; 1993 Jul; 37(2):105-11. PubMed ID: 8319241 [TBL] [Abstract][Full Text] [Related]
15. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. Ratliff TL; Gillen D; Catalona WJ J Urol; 1987 Jan; 137(1):155-8. PubMed ID: 3491909 [TBL] [Abstract][Full Text] [Related]
16. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer. Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V Front Immunol; 2020; 11():615091. PubMed ID: 33584702 [TBL] [Abstract][Full Text] [Related]
17. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010 [TBL] [Abstract][Full Text] [Related]
19. Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer. Gan YH; Zhang Y; Khoo HE; Esuvaranathan K Eur J Cancer; 1999 Jul; 35(7):1123-9. PubMed ID: 10533458 [TBL] [Abstract][Full Text] [Related]
20. [Intravesical instillation of BCG for the bladder cancer: relationship between effect and immune cells in peripheral blood and bladder wall]. Chen LZ Zhonghua Wai Ke Za Zhi; 1993 Jun; 31(6):336-8. PubMed ID: 8313752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]